Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DDO | Q99489 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064103 | 1.00 | HCAR2 (0.63) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3500223 | 0.91 | MKNK1 (0.55) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Acetic Acid SCHEMBL28240357 | 0.88 | HCAR2 (0.65) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL51830 | 0.88 | HCAR2 (0.70) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7661020 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19987838 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Bromide SCHEMBL21332093 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Fluoride SCHEMBL21331909 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7124062 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1117746 | 0.85 | HCAR2 (0.67) | HCAR2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | MIRALOGX LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | MIRALOGX LLC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230039858-A1 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | INTOCELL, INC. (KR) | 2023-02-09 | — | — | US | disclosed |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2021-08-10 | — | — | US | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| WO-2021111185-A1 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | INTOCELL, INC. (KR) | 2021-06-10 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-28 | — | — | US | disclosed |
| EP-2595482-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-03 | — | — | US | disclosed |
| CN-101263130-B | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA NV | 2011-03-09 | — | — | CN | disclosed |
| CN-101263130-A | 2-aniline-4-aryl substituted thiazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | HMOX1, FECH, SLC40A1 | HCAR2 2999/4885ALDH1A1 1350/4885KDM4E 1720/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | HCAR2 505/4885ALDH1A1 900/4885KDM4E 1492/4885 |
| US-20110269748-A1 | 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES | CHRNA4, CHRNA5, CHRNA7 | HCAR2 37/4885ALDH1A1 582/4885KDM4E 3173/4885 |
| US-20230039858-A1 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | FCGR2A, FCGRT, FCGR3B | HCAR2 3704/4885ALDH1A1 200/4885KDM4E 3090/4885 |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP11B2, HSD11B2 | HCAR2 872/4885ALDH1A1 300/4885KDM4E 3294/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HCAR2 3226/4885ALDH1A1 1469/4885KDM4E 911/4885 |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | HCAR2 505/4885ALDH1A1 900/4885KDM4E 1492/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | HCAR2 3226/4885ALDH1A1 1469/4885KDM4E 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.